FTRE

Fortrea Holdings Inc

Add to Watchlist

Advanced Chart

6.360

-0.51(-7.424%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

6.850

Open

6.850

VWAP

Vol

1.58M

Mkt Cap

575.58M

Low

6.235

Amount

EV/EBITDA(TTM)

Total Shares

89.37M

1.73B

EV/OCF(TTM)

10.56

P/S(TTM)

0.23

Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

631.46M

-4.67%

0.075

-350.87%

611.32M

-9.42%

0.149

-35.35%

613.87M

-11.93%

0.210

+16.61%

Estimates Revision

The market is revising Upward the revenue expectations for Fortrea Holdings Inc. (FTRE) for FY2025, with the revenue forecasts being adjusted by 1% over the past three months. During the same period, the stock price has changed by 0.47%.

Revenue Estimates for FY2025

Revise Upward

+1%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+6.51%

In Past 3 Month

Stock Price

Go Up

+0.47%

In Past 3 Month

10 Analyst Rating

-7.86% Downside

Wall Street analysts forecast FTRE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FTRE is 5.86 USD with a low forecast of 4.75 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

8 Hold

2 Sell

Hold

-7.86% Downside

Current: 6.360

Low

4.75

Averages

5.86

High

8.00

-7.86% Downside

Current: 6.360

Low

4.75

Averages

5.86

High

8.00

Mizuho

Neutral

downgrade

$8 -> $7

2025-07-11

Reason

Mizuho

Price Target

$8 -> $7

2025-07-11

downgrade

Neutral

Reason

Mizuho lowered the firm's price target on Fortrea to $7 from $8 and keeps a Neutral rating on the shares as part of a Q2 earnings preview. The firm believes earnings visibility is solid for the hospital group while cost trends remain challenging for managed care companies. Mizuho says its survey of 215 physicians is positive for hospitals, neutral for clinical labs, and neutral-to-negative for managed care.

Citi

Neutral

maintain

2025-05-22

Reason

Citi

Price Target

2025-05-22

maintain

Neutral

Reason

Mizuho

Neutral

downgrade

$10 -> $8

2025-05-14

Reason

Mizuho

Price Target

$10 -> $8

2025-05-14

downgrade

Neutral

Reason

Mizuho lowered the firm's price target on Fortrea to $8 from $10 and keeps a Neutral rating on the shares. The company reported a good Q1 earnings beat, but reported weaker than expected bookings trends driven by delays in awards for biotech clients and soft demand in clinical pharmacology, the analyst tells investors in a research note. The firm expects the funding backdrop and volatile macroeconomic environment coupled with the loss of its CEO to continue to put pressure on Fortrea.

TD Cowen

Charles Rhyee

Hold

downgrade

$7 -> $5

2025-05-14

Reason

TD Cowen

Charles Rhyee

Price Target

$7 -> $5

2025-05-14

downgrade

Hold

Reason

TD Cowen analyst Charles Rhyee lowered the firm's price target on Fortrea to $5 from $7 and keeps a Hold rating on the shares. The firm updated estimates to reflect continued soft biotech and large pharma.

Barclays

Luke Sergott

Underweight

downgrade

$6 -> $5

2025-05-13

Reason

Barclays

Luke Sergott

Price Target

$6 -> $5

2025-05-13

downgrade

Underweight

Reason

Barclays analyst Luke Sergott lowered the firm's price target on Fortrea to $5 from $6 and keeps an Underweight rating on the shares. The company's CEO is stepping down and it reported a bookings miss on big sales beat, the analyst tells investors in a research note. The firm expects the shares to respond positively outside of commentary that things are getting materially worse.

Barclays

Luke Sergott

Hold

Sell

Downgrades

$12 → $6

2025-04-10

Reason

Barclays

Luke Sergott

Price Target

$12 → $6

2025-04-10

Downgrades

Hold

Sell

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Fortrea Holdings Inc (FTRE.O) is 13.19, compared to its 5-year average forward P/E of 28.64. For a more detailed relative valuation and DCF analysis to assess Fortrea Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

28.64

Current PE

13.19

Overvalued PE

45.27

Undervalued PE

12.01

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

13.19

Current EV/EBITDA

9.79

Overvalued EV/EBITDA

17.08

Undervalued EV/EBITDA

9.31

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

0.73

Current PS

0.25

Overvalued PS

1.03

Undervalued PS

0.43

Financials

Annual

Quarterly

FY2025Q1

YoY :

-1.63%

651.30M

Total Revenue

FY2025Q1

YoY :

-27.27%

-24.80M

Operating Profit

FY2025Q1

YoY :

+605.39%

-562.90M

Net Income after Tax

FY2025Q1

YoY :

+453.10%

-6.25

EPS - Diluted

FY2025Q1

YoY :

+264.18%

-127.10M

Free Cash Flow

FY2025Q1

YoY :

+14.63%

14.89

Gross Profit Margin - %

FY2025Q1

YoY :

+43.24%

5.40

FCF Margin - %

FY2025Q1

YoY :

+617.26%

-86.43

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

35.2K

USD

3-6

Months

49.2K

USD

6-9

Months

237.4K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

2.5M

Volume

3-6

Months

2.0M

Volume

6-9

Months

1.9M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.2M

Volume

Months

6-9

2.0M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

8.0K

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

35.2K

USD

3-6

Months

49.2K

USD

6-9

Months

237.4K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

FTRE News & Events

Events Timeline

2025-06-24 (ET)

2025-06-24

07:06:13

Fortrea announces strategic collaboration with Emery Pharma

2025-06-12 (ET)

2025-06-12

08:42:18

Fortrea adopts limited-duration stockholder rights plan

2025-06-11 (ET)

2025-06-11

16:13:22

Fortrea names Anshul Thakral as CEO

News

7.0

07-29PRnewswire

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings

7.0

07-29Globenewswire

DEADLINE ALERT for FTRE, VSTS: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

7.0

07-28Globenewswire

FORTREA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Fortrea Holdings (FTRE) of The August 1st Deadline and Urges Investors to Contact The Firm